Our Technology
We employ a multidisciplinary platform that integrates advanced computational modeling, high-throughput screening, and systematic enzyme optimization. This unified approach allows us to design, test, and refine enzymes with exceptional speed and precision.
Arium Biolabs leverages naturally occurring human enzymes as templates to engineer “designer enzymes’’ capable of breaking down unwanted or harmful compounds in the body. These engineered enzymes form the basis of a new class of biotherapies aimed at treating substance-abuse disorders and a broad range of metabolic diseases. Having already developed our core technological foundation, we are now applying it to create therapeutic candidates targeting fentanyl and methamphetamine addiction—areas of urgent unmet medical need.
Our platform combines deep expertise in enzyme engineering and protein design with high-throughput computational screening and state-of-the-art machine learning and artificial intelligence. This integration accelerates every stage of discovery, enabling Arium Biolabs to move from concept to optimized enzyme candidates dramatically faster and at significantly lower cost than traditional development pathways. The result is a scalable, data-driven engine for designing next-generation biological therapeutics.
- Computational Modeling: Predictive molecular simulations that guide and refine enzyme design.
- Latest Technology: Machine learning and artificial intelligence to rapidly explore vast design spaces.
- High-Throughput Assays: Strategic collaborations with CROs for fast, efficient, and reliable experimental testing of engineered enzymes.
IP Portfolio/Current Patents
- US 11,621,053 B2: Computational systems and methods for discovering allosteric sites and allosteric modulators of proteins — Pratul K. Agarwal, Arium BioLabs LLC. Issued: 2023-04-04.
- US 12,087,410 B2: Systems and methods of designing chemical libraries for allosteric modulator discovery — Pratul K. Agarwal, Arium BioLabs LLC. Issued: 2024-09-10.
- US 12,326,454 B2: Systems and methods for identifying positive allosteric modulators of enzymes to enhance activity — Pratul K. Agarwal, Arium BioLabs LLC. Issued: 2025-06-10.
- US 12,340,872 B2: Systems and methods for engineering enzymes using identified energy transfer networks — Pratul K. Agarwal, Arium BioLabs LLC. Issued: 2025-06-24.
Key Capabilities
- Computationally driven evaluation of hundreds of thousands of engineered enzyme variants, enabling rapid identification of the most promising candidates for therapeutic and industrial use.
- A unique scientific approach for identifying and exploiting allosteric sites, advancing both drug design and enzyme engineering with unprecedented precision.
- Flexible and scalable technology platforms that support the development of therapeutics, diagnostics, and high-performance industrial biocatalysts.
- A proprietary enzyme-engineering platform and intellectual property portfolio available for collaborations, co-development projects, and strategic external partnerships.